First Dallas Securities Inc. Gilead Sciences, Inc. Transaction History

First Dallas Securities Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 11, 2019	SELL	$60.54 - $79.0 $201,295 - $262,675	-3,325 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$71.28 - $78.92 $35,640 - $39,460	500 Added 17.7%	3,325 $257,000
Q2 2018 Jul 31, 2018	SELL	$64.88 - $75.68 $57,872 - $67,506	-892 Reduced 24.0%	2,825 $200,000
Q1 2018 May 04, 2018	SELL	$72.84 - $88.8 $23,673 - $28,860	-325 Reduced 8.04%	3,717 $280,000
Q4 2017 Feb 07, 2018	SELL	$71.15 - $83.52 $89,577 - $105,151	-1,259 Reduced 23.75%	4,042 $290,000
Q3 2017 Nov 07, 2017	SELL	$72.11 - $85.47 $3,605 - $4,273	-50 Reduced 0.93%	5,301 $429,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,351	5,351 $379,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of First Dallas Securities Inc., based on Form 13F filings with the SEC.

Stay updated on First Dallas Securities Inc. with notifications on news.